Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial

  • Batool Hossein-Rashidi Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran
  • Bahareh Khandzad Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran
  • Ensieh Shahrokh-Tehraninejad Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran
  • Maryam Bagheri Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran
  • Mansoureh Gorginzadeh Tehran University of Medical Sciences, Tehran, Iran
Keywords: Polycystic Ovary Syndrome, Clomiphene Citrate, Recombinant FSH, Ovulation Induction

Abstract

Objective: Since there is still controversy regarding the best first-line choice for ovulation induction (OI) other than clomiphene citrate (CC) in infertile women diagnosed with polycystic ovary syndrome (PCOS), the aim of the present study was to compare recombinant human FSH with CC as the first course of OI in these women.Materials and methods: In this pilot randomized controlled trial, 104 infertile women diagnosed with PCOS were randomized in two groups to receive either CC with the dose of 100mg per day from day 3 of a spontaneous or progestin-induced menstruation for 5 days or rFSH with the starting dose of 50 IU daily {and weekly dose increment of as low as 12.5 IU}, on the day4 of the cycle. They were assessed during a single OI course. The pregnancy rate (PR) and live birth rate (LBR) were the primary outcomes. The follicular response, endometrial thickness, cancellation of the cycles and ovarian hyper stimulation (OHSS) rate were the secondary outcomes.Results: Analyzing data of 96 patients using Chi2 and Fischer’s Exact test (44 in rFSH group and 52 in CC group), both PR and LBR were comparable in the two groups {13.6% vs. 9.6% and 11.4% vs. 9.6% respectively}, with the difference not to be significant (p > 0.05). No cases of OHSS or multiple gestations happened during the treatment course.Conclusion: It seems that rFSH is as efficacious as CC while not with more complications for the first-line OI in infertile women with PCOS. However, due to the limitations of the present study including the small population and the single cycle of treatment, our results did not come out to prove this and more studies with larger study population are needed to compare the cumulative PR and LBR.

References

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25.

Moghetti P, Carmina E, De Leo V, Lanzone A, Orio F, Pasquali R. How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology. J Endocrinol Invest 2015; 38: 1025-37.

ESHRE Capri Workshop Group. Health and fertility in World Health Organization group 2 anovulatory women. Human Reproduction Update 2012; 18: 586-99.

Fields E, Chard J, James D, Treasure T, Guideline Development Group. Fertility (update): summary of NICE guidance. BMJ 2013; 346: f650.

Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod 2008; 23: 462-77.

Homburg R. Polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2008; 22: 261–74.

Nahuis MJ, Weiss NS, Van der veen F, Mol BW, Hampes PG, Oosterhuis J, et al. The M-OVIN study: does switching treatment to FSH and / or IUI lead to higher pregnancy rates in a subset of women with world health organization type II anovulation not conceiving after six ovulatory cycles with clomiphene citrate – a randomized controlled trial. BMC Women's Health 2013; 13: 42.

Ghanem ME, Elboghady LA, Hassan M, Gibreel A, Houssen M, Shaker ME, et al. Clomiphene Citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial. J Assist Reprod Genet 2013; 30: 1477-85.

Eijkemans MJ, Habbema JD, Fauser BC. Characteristics of the best prognostic evidence: an example on prediction of outcome after clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. Semin Reprod Med 2003; 21: 39–47.

Palomba S, Falbo A, Zullo F. Management strategies for ovulation induction in women with polycystic ovary syndrom and known clomiphene citrate resistance. Curr Opin Obstet Gynecol 2009; 21: 465–73.

Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. Clomiphene and anti-estrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 2009; 4: CD002249.

Bayram N, vanWely M, van Der Veen F. Recombinant FSH versus urinary gonadotropins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2001; 2:CD002121.

Balen A. Ovulation induction for polycystic ovary syndrome. Hum Fertil (Camb) 2000; 3:106-11.

Bouchard P. Treatment of infertility in women with polycystic ovary syndrome. Ann Endocrinol (Paris) 2010; 71: 225-7.

Homburg R, Howles CM. Low-dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: rationale, results, reflections and refinements. Hum Reprod Update 1999; 5:493–9.

Lan VT, Norman RJ, Nhu GH, Tuan PH, Tuong HM. Ovulation induction using low-dose step-up rFSH in Vietnamese women with polycystic ovary syndrome. Reprod Biomed Online 2009; 18: 516-21.

Orvieto R, Homburg R. Chronic ultra-low dose follicle-stimulating hormone regimen for patients with polycystic ovary syndrome: one click, one follicle, one pregnancy. Fertil Steril 2009; 91:1533-5.

Lopez E, Gunby J, Daya S, parrilla JJ, Abad L, Balasch J. Ovulation induction in women with polycystic ovarian syndrome: randomized trial of clomiphene citrate versus low dose recombinant FSH as first line therapy. Reprod Biomed Online 2004; 9: 382-90.

Homburg R, Hendriks M.L, König TE, Anderson RA, Balen AH, Brincat M, et al. Clomiphene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. Hum Reprod 2012; 27: 468-73.

Spritzer PM, Motta AB, Sir-Petermann T, Diamanti-Kandarakis E. Novel strategies in the management of polycystic ovary syndrome. Minerva Endocrinol 2015; 40: 195-212.

Homburg R. Ovulation Induction and Controlled Ovarian Stimulation. Springer International Publishing

Switzerland 2014; chapter 9: 87-95.

Bazarganipour F, Taghavi SA, Montazeri A, Ahmadi F, Chaman R, Khosravi A. The impact of polycystic ovary syndrome on the health-related quality of life: A systematic review and meta-analysis. Iran J Reprod Med 2015; 13: 61-70.

Biljan MM, Hemmings R, Brassard N.The Outcome of 150 Babies Following the Treatment WithLetrozole or Letrozole and Gonadotropins. Fertility and Sterility 2005; 84: S95.

Lan KC, Huang FJ, Lin YC, Kung FT, Lan TH, Chang SY. Significantly superiorresponse in the right ovary compared with the left ovary after stimulation withfollicle-stimulating hormone in a pituitary down-regulation regimen. Fertil steril 2010; 93:2269-73.

Thomson AJ, Gazvani MR, Wood SJ, Meacock SC, Lewis-Jones DI, Kingsland CR. Comparison of ovarian response in right and left ovaries in IVF patients. Hum Reprod 2001; 16:1694–7.

Published
2016-05-15
How to Cite
1.
Hossein-Rashidi B, Khandzad B, Shahrokh-Tehraninejad E, Bagheri M, Gorginzadeh M. Recombinant FSH Compared to Clomiphene Citrate as the First-Line in Ovulation Induction in Polycystic Ovary Syndrome Using Newly Designed Pens: A Randomized Controlled Trial. J Fam Reprod Health. 10(1):42- 48.
Section
Original Articles